We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Hoth Therapeutics has reached an agreement with Voltron Therapeutics to form a joint venture entity, to be named HaloVax, to commence preclinical studies.
Hoth Therapeutics has collaborated with Voltron Therapeutics to establish a joint venture (JV), HaloVax, for preclinical studies of vaccine candidates against Covid-19.